Randy Gelow, MD
Family Medicine · Phoenix, AZNPI 1568755130
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,425 of the $56,187 with a category attached, or 63.0%. Viiv Healthcare Company accounts for 86.9% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $31,437, more than ten times the $968 reported in 2019. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 546 payments — averaging $102.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$49K
- Gilead$4K
- Merck$848
- Braeburn Inc.$372
- Napo Pharmaceuticals Inc$367
- Novo Nordisk$348
- plus $2K from 23 others
Across 2 payments — averaging $6237.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$12K
What the payments were for
- Speaking & faculty fees$35,42563%
- Travel & lodging$6,05111%
- Food & beverage$14,08625%
- Education$4481%
- Gifts$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 291 | $48,808 |
| Gilead | 119 | $3,818 |
| Merck | 32 | $848 |
| Braeburn Inc. | 16 | $372 |
| Napo Pharmaceuticals Inc | 28 | $367 |
| Novo Nordisk | 3 | $348 |
| Janssen Scientific Affairs, LLC | 3 | $240 |
| Indivior Inc. | 5 | $184 |
| Medtronic | 5 | $139 |
| Saluda Medical Americas, Inc. | 3 | $120 |
| EMD Serono, Inc. | 5 | $119 |
| Organon | 2 | $115 |
| Janssen Products, LP | 1 | $100 |
| Amgen | 5 | $87 |
| AstraZeneca | 4 | $73 |
| Johnson & Johnson | 5 | $70 |
| Boehringer Ingelheim | 3 | $68 |
| Alkermes, Inc. | 2 | $44 |
| Exact Sciences | 2 | $44 |
| AbbVie | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Abiomed | 1 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Pfizer | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,187 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 272 | $1,149,712 |
| DescovyEmtricitabine/Tenofov Alafenam | 76 | $192,189 |
| DovatoDolutegravir Sodium/Lamivudine | 43 | $133,983 |
| PrezcobixDarunavir/Cobicistat | 39 | $117,120 |
| TivicayDolutegravir Sodium | 40 | $87,688 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 18 | $71,127 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $56,440 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 13 | $36,871 |
| Wellbutrin XlBupropion Hcl | 11 | $29,078 |
| MounjaroTirzepatide | 26 | $27,607 |
| TrulicityDulaglutide | 23 | $23,296 |
| JardianceEmpagliflozin | 20 | $20,341 |
| EliquisApixaban | 12 | $20,329 |
| PifeltroDoravirine | 12 | $19,881 |
| EdurantRilpivirine Hcl | 11 | $18,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $3,818 | $1,341,901348 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq | $48,808 | $278,11196 claims |
| Johnson & JohnsonPrezcobix | $70 | $117,12039 claims |
| MerckDelstrigo, Pifeltro, Janumet Xr | $848 | $69,41341 claims |
| Lilly USA, LLCMounjaro, Trulicity | $17 | $50,90449 claims |
| Boehringer IngelheimJardiance | $68 | $20,34120 claims |
| PfizerEliquis | $15 | $20,32912 claims |
| Janssen Scientific Affairs, LLCEdurant | $240 | $18,55611 claims |
| AstraZenecaSymbicort | $73 | $3,62011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
- James BeachPhoenix$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.